Abstract Library

#2967 Longitudinal Changes in Plasma 5-Hydroxyindoleacetic Acid (5-HIAA) and Other Biomarkers during Treatment of Functional Midgut Neuroendocrine Tumours (NETs) with Lanreotide Autogel: CALM NET Study Results

Introduction: CALM-NET (EudraCT 2013-002194-22; NCT02075606) evaluated pre-treatment circulating tumour cell levels in patients with NETs as a predictor of response to lanreotide autogel (LAN).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Shah T, Caplin M, Khan M, Houchard A, Furnace M,

Keywords: neuroendocrine tumours, lanreotide, biomarkers,

#2833 Surgical Correction of Carcinoid Heart Disease Improves Liver Function and 5-Hydroxyindoleacetic Acid Levels

Introduction: Neuroendocrine tumours of the gastrointestinal tract cause carcinoid syndrome and carcinoid heart disease. These tumours secrete serotonin, which can bind to heart valves and cause fibrosis and valve incompetence. Most cases involve the tricuspid valve +/- pulmonary valve. Medical management comprises diuretics for fluid overload and somatostatin analogues to reduce circulating serotonin. Definitive treatment is heart-valve replacement surgery which improves exercise tolerance but has high perioperative mortality. We have previously reported that valve-replacement surgery can reduce 5-hydroxyindoleacetic acid (5-HIAA) levels, reflecting a decline in hormone activity.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Shah H

Authors: Shah H, Sagar V, Venkataraman H, Steeds R, Rooney S,

Keywords: carcinoid, carcinoid syndrome, neuroendocrine tumour, carcinoid heart disease, 5hiaa,

#2750 Progression-Free Survival and Clinical Outcomes with Long-Term Use of Telotristat Ethyl in US Clinical Practice

Introduction: Treatment of advanced neuroendocrine tumors aims to relieve symptoms and suppress tumor growth. Primary findings from the TELEACE study suggested telotristat ethyl (TE) may reduce tumor size and impact tumor growth.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Metz D

Authors: Metz D, Liu E, Joish V, Huynh L, Cheng M,

Keywords: neuroendocrine tumor, carcinoid syndrome, telotristat ethyl, serotonin, tumor growth, progression-free survival,

#2219 24 Hour Urinary 5-Hydroxyindoleacetic Acid Levels in Patients with Non-Functioning Pancreatic Neuroendocrine Tumors

Introduction: The secretion of urinary 5-Hydroxyindoleacetic Acid (u5-HIAA) by non-functioning PNETs (NF-PNET) has rarely been reported, and the data on the association between u5-HIAA levels and disease burden is scant.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Tirosh A

Authors: Tirosh A, Papadakis G, Sadowsi S, Patel D, Nilubol N,

Keywords: 5-HIAA, PNET, Secretion, Biomarker,

#2103 Neuroendocrine Tumors in the Chilean Population

Introduction: In recent years, neuroendocrine tumors (NETs) have shown a significant raise in prevalence and incidence. However this observation needs to be accurately quantified using reliable epidemiological databases.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Carrillo D

Authors: Carrillo D, Valenzuela Y, Pinto M, Retamal I, Balmaceda C,

Keywords: Neuroendocrine, Carcinoid, Registry, 5-Hydroxyindoleacetic acid, Serotonin, Chromogranin A,